• 1
    Chiang, B. N., L. V. Perlman, M. Fulton, L. D. Jr Ostrander, and F. H. Epstein. 1970. Predisposing factors in sudden cardiac death in Tecumseh, Michigan. A prospective study. Circulation 41:3137.
  • 2
    Packer, M. 1992. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 85(Suppl. 1):I50I56.
  • 3
    Elkon, K. B., T. A. Swerdlow, and D. P. Myburgh. 1977. Persistent ventricular ectopic beats: a long-term study. S. Afr. Med. J. 52:564566.
  • 4
    Rodstein, M., L. Wolloch, and R. S. Gubner. 1971. Mortality study of the significance of extrasystoles in an insured population. Circulation 44:617625.
  • 5
    Kennedy, H. L., J. A. Whitlock, M. K. Sprague, L. J. Kennedy, T. A. Buckingham, and R. J. Goldberg. 1985. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. N. Engl. J. Med. 312:193197.
  • 6
    Bikkina, M., M. G. Larson, and D. Levy. 1992. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. Ann. Intern. Med. 117:990996.
  • 7
    Barrett, P. A., C. T. Peter, H. J. Swan, B. N. Singh, and W. J. Mandel. 1981. The frequency and prognostic significance of electrocardiographic abnormalities in clinically normal individuals. Prog. Cardiovasc. Dis. 23:299319.
  • 8
    Fleg, J. L., and H. L. Kennedy. 1992. Long-term prognostic significance of ambulatory electrocardiographic findings in apparently healthy subjects greater than or equal to 60 years of age. Am. J. Cardiol. 70:748751.
  • 9
    Talpaz, M., N. P. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354:25312541.
  • 10
    Hochhaus, A., H. M. Kantarjian, M. Baccarani, J. H. Lipton, J. F. Apperley, B. J. Druker, et al. 2007. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:23032309.
  • 11
    Kantarjian, H., N. P. Shah, A. Hochhaus, J. Cortes, S. Shah, M. Ayala, et al. 2010. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. 362:22602270.
  • 12
    Saglio, G., D. W. Kim, S. Issaragrisil, P. le Coutre, G. Etienne, C. Lobo, et al. 2010. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 362:22512259.
  • 13
    Cortes, J. E., M. Baccarani, F. Guilhot, B. J. Druker, S. Branford, D. W. Kim, et al. 2010a. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol. 28:424430.
  • 14
    Shah, N. P., H. M. Kantarjian, D. W. Kim, D. Rea, P. E. Dorlhiac-Llacer, J. H. Milone, et al. 2008. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26:32043212.
  • 15
    WHO-UMC. 2012. The use of the WHO-UMC system for standardised case causality assessment [cited 07.02.2012]. Available at (accessed 19 June 2013).
  • 16
    Shah, N. P., C. Tran, F. Y. Lee, P. Chen, D. Norris, and C. L. Sawyers. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399401.
  • 17
    Orphanos, G. S., G. N. Ioannidis, and A. G. Ardavanis. 2009. Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol. 48:964970.
  • 18
    Hochhaus, A., M. Baccarani, M. Deininger, J. F. Apperley, J. H. Lipton, S. L. Goldberg, et al. 2008. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 22:12001206.
  • 19
    Kantarjian, H., R. Pasquini, V. Levy, S. Jootar, J. Holowiecki, N. Hamerschlak, et al. 2009. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 115:41364147.
  • 20
    Cortes, J. E., D. Jones, S. O'Brien, E. Jabbour, F. Ravandi, C. Koller, et al. 2010b. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 28:398404.
  • 21
    Francis, J., M. S. Ahluwalia, M. Wetzler, E. Wang, P. Paplham, S. Smiley, et al. 2010. Reversible cardiotoxicity with tyrosine kinase inhibitors. Clin. Adv. Hematol. Oncol. 8:128132.
  • 22
    Schmidinger, M., C. C. Zielinski, U. M. Vogl, A. Bojic, M. Bojic, C. Schukro, et al. 2008. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26:52045212.
  • 23
    Bristol.Myers Squibb. 2010. Sprycel. Summary of product characteristics[cited 17.01.2012]. Available at (accessed 19 June 2013).
  • 24
    Brave, M., V. Goodman, E. Kaminskas, A. Farrell, W. Timmer, S. Pope, et al. 2008. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin. Cancer Res. 14:352359.
  • 25
    WHO-UMC. 2011. Caveat document accompanying statement to data released from the Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring. [cited 07.02.2012]; Available at (accessed 19 June 2013).
  • 26
    Lerman, B. B., K. Stein, E. D. Engelstein, D. S. Battleman, N. Lippman, D. Bei, et al. 1995. Mechanism of repetitive monomorphic ventricular tachycardia. Circulation 92:421429.
  • 27
    Lerman, B. B., K. M. Stein, and S. M. Markowitz. 1996. Adenosine-sensitive ventricular tachycardia: a conceptual approach. J. Cardiovasc. Electrophysiol. 7:559569.